3 Key Reasons to Attend the 5th Drug Safety conference in London
Drug Safety 2018
The UK is a great place for early-stage research – but NHS red tape and market access remain major barriers.
Brexit is already forcing parts of the medical device sector to leave the UK – will pharma have to follow?
A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.